EUVIMEDEUVIMED entdecken
Crossref

Plasma 21-deoxycortisone: a sensitive additive tool in 21-hydroxylase deficiency in newborns

Jean Fiet, Guillaume Bachelot iD, Coumba Sow, Dominique Farabos, Nicolas Helin, Thibaut Eguether, Marie-Noelle Dufourg, Christine Bellanne-Chantelot, Bettina Ribaut, Anne Bachelot, Jacques Young, Muriel Houang und 1 weitere

European Journal of Endocrinology · 2024

DOI: 10.1093/ejendo/lvae062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Jean Fiet und 12 weiteren Autor:innen. Beteiligte Einrichtung: Département de Métabolomique Clinique, Hôpital Saint Antoine, AP-HP.Sorbonne Université, 27 Rue Chaligny, 75012 Paris, France. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Cortodoxone, Biomarkers. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: DIM "Thérapie Génique", DIM “Thérapie Génique”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective, Design, and Methods Although 17-hydroxyprogesterone (17OHP) has historically been the steroid assayed in the diagnosis of congenital adrenal 21-hydroxylase deficiency (CAH-21D), its C11-hydroxylated metabolite, 21-deoxycortisol (21DF), which is strictly of adrenal origin, is assayed in parallel in this pathology. This steroid (21DF) is oxidized by 11beta-hydroxysteroid dehydrogenase type 2 into 21-deoxycortisone (21DE). In the context of CAH-21D confirmation testing, confounding factors (such as intensive care unit admission, stress, prematurity, early sampling, and variations of sex development) can interfere with the interpretation of the gold-standard biomarkers (17OHP and 21DF). Since its tissue concentrations are especially high in the placenta, we hypothesized that 21DE quantification in the neonatal periods could be an interesting biomarker in addition to 17OHP and 21DF. To verify this hypothesis, we developed a new mass spectrometry-based assay for 21DE in serum and applied it to newborns screened for CAH-21D.

Results

In newborns with CAH-21D, the mean serum levels of 21DE reached 17.56 ng/mL (ranging from 8.58 ng/mL to 23.20 ng/mL), and the mean 21DE:21DF ratio was 4.99. In contrast, in newborns without CAH-21D, the 21DE serum levels were low and not statistically different from the analytical 21DE limit of quantification (0.01 ng/mL).

Conclusion

Basal serum 21DE appears to be a novel sensitive and specific biomarker of CAH-21D in newborns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Hyperplasia, CongenitalCortodoxoneBiomarkersHumansInfant, NewbornFemaleMale17-alpha-HydroxyprogesteroneNeonatal ScreeningSensitivity and Specificity

Stichwörter der Autor:innen

11β-HSD2: 11beta-hydroxysteroid dehydrogenase type 217OHP: 17-hydroxyprogesterone21DE: 21-deoxycortisone21DF: 21-deoxycortisol21OHD: 21-hydroxylase deficiencyE: cortisoneF: cortisolNBS: newborn screening

Substanzen

21-deoxycortisolCortodoxoneBiomarkers17-alpha-Hydroxyprogesterone

Autor:innen und Institutionen

  • Département de Métabolomique Clinique, Hôpital Saint Antoine, AP-HP.Sorbonne Université, 27 Rue Chaligny, 75012 Paris, France.
  • Sorbonne Université, Saint Antoine Research Center, INSERM UMR 938, 75012 Paris, France.
  • Service de Biologie de La Reproduction-CECOS, Hôpital Tenon, AP-HP.Sorbonne Université, 75020 Paris, France.
  • Explorations Fonctionnelles Endocriniennes, Hôpital Armand Trousseau, AP-HP, 26 Av Dr Netter, Paris 75012, France.
  • Sorbonne Université, Département de Génétique Médicale, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France.
  • Sorbonne Université, Service d'endocrinologie et médecine de la reproduction, IE3M, Hôpital Pitié-Salpêtrière, AP-HP, F-75013 Paris, France.

ORCID-Profile: Guillaume Bachelot, Antonin Lamazière

Förderung

  • DIM "Thérapie Génique"
  • DIM “Thérapie Génique”

Zitieren

APA

Fiet, J., Bachelot, G., Sow, C., Farabos, D., Helin, N., Eguether, T., Dufourg, M. N., Bellanne-Chantelot, C., Ribaut, B., Bachelot, A., Young, J., Houang, M., & Lamazière, A. (2024). Plasma 21-deoxycortisone: a sensitive additive tool in 21-hydroxylase deficiency in newborns. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae062

Vancouver

Fiet J, Bachelot G, Sow C, Farabos D, Helin N, Eguether T, et al. Plasma 21-deoxycortisone: a sensitive additive tool in 21-hydroxylase deficiency in newborns. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae062

BibTeX
@article{Fiet2024,
  author = {Fiet, Jean and Bachelot, Guillaume and Sow, Coumba and Farabos, Dominique and Helin, Nicolas and Eguether, Thibaut and Dufourg, Marie-Noelle and Bellanne-Chantelot, Christine and Ribaut, Bettina and Bachelot, Anne and Young, Jacques and Houang, Muriel and Lamazière, Antonin},
  title = {Plasma 21-deoxycortisone: a sensitive additive tool in 21-hydroxylase deficiency in newborns},
  journal = {European Journal of Endocrinology},
  year = {2024},
  doi = {10.1093/ejendo/lvae062}
}
Kostenlos starten →